Nadine S. McCarthy
nadine.mccarthy.wg12@
wharton.upenn.edu University of Cambridge, UK B.A., Natural Sciences, 2005
Kirk R. McConnell
kirk.mcconnell.wg12@
wharton.upenn.edu Stanford University, Palo Alto, CA B.A., Human Biology, 2007
Michael C. Meng
michael.meng.wg12@
wharton.upenn.edu University of Michigan Ross School of Business, Ann Arbor, MI B.B.A., High Distinction, Finance and Accounting, 2006
An opportunity to serve in commercial management within the healthcare industry.
Novartis Pharmaceuticals, East Hanover, NJ Summer Associate, New Products & Licensing, Summer 2011 Led cross-functional team to evaluate the optimal promotion strategy for a phase III pipeline product. Led a review of the U.S. COPD device strat- egy and evaluated demand for an up- graded device through physician and payer research. Developed a workshop on the Patient Journey and presented outcomes to senior management; task-force set up to address identified areas of opportunity.
Monitor Group, London / Zurich Engagement Manager, 2005-2010 Focused on corporate strategy, busi- ness development and marketing in the healthcare industry. Four years of managerial experience with between 2 to 4 direct reports on average. Led a team to develop the drug launch strategy for a new biologic with a market potential of $2B. Defined a global portfolio strategy for female contraceptives (€2.6B annual sales). Advised board on commercial options for a Phase II pharmaceutical product. Prepared proposals of new business and participated in sales process. Received special recognition for developing new client methodology and presented methodology to all senior partners at Europe-wide meeting.
An opportunity to improve healthcare delivery through a role in strategy or operations management.
Kaiser Permanente, Oakland, CA Customer Analytics and Business Marketing Intern, Summer 2011 Identified and developed opportuni- ties to better use internal data re- sources to demonstrate value Kaiser Permanente provides to customers. Strengthened process management of cross-departmental analytical report- ing capabilities, elevating the quality of deliverables while also enhancing operational efficiency.
The Zitter Group, San Francisco, CA Manager of Syndicated Research, 2008-2010 Senior Analyst, 2008 Analyst, 2007-2008 Authored 6 annual, multi-client research reports that provided pharmaceutical industry clients with comprehensive understanding of U.S. healthcare system, largely focused on issues related to managed care. Lever- aged people and process management skills to lead a cross-functional team through content ideation, data collection, report development and sales/client management, resulting in on-time and highly marketable final deliverables that generated the high- est revenue levels in company’s history. Transformed research findings into actionable strategic recommendations and worked with clients to define optimal managed care strategies and opportunities to improve perform- ance. Communicated findings through in-person presentations, published articles, and speaking at professional conferences.
An opportunity in the alternative invest- ments industry focused on healthcare.
Moore Capital, New York, NY Summer intern, Summer 2011 Analyze securities as it relates to the macroeconomic environment including a variety of areas such as credit, rates, equities, commodities, and currencies.
Apax Partners, New York, NY Associate, 2008-2010 Identify, evaluate, and execute private equity investments focusing on health- care for Apax Europe VII ($16B global fund); monitor and improve portfolio companies. Key projects: potential $550M acquisition of a controlling stake in a leading lab diagnostics business in Brazil and Qualitest Phar- maceuticals (portfolio company), a generic pharmaceutical manufacturer based in the U.S.
Lazard Frères & Co., New York, NY Analyst, 2006-2008 Working as part of the investment banking team as the financial analyst focused on mergers and acquisitions in the healthcare industry. Key projects: advising a large global pharmaceutical company on the potential $6.3B groundbreaking acquisition of one of the largest Indian generic pharmaceu- tical companies and advising UCB on the $6.1B transformational cross- border acquisition of Schwarz Pharma.
19
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40